A method for overcoming antibiotic resistance uses multimodal nanoparticles that target bacterial defence mechanisms while enhancing the innate immune response. The rise in antibiotic resistance is considered a slow-moving medical catastrophe, as these revolutionary drugs that have kept us relatively safe from bacterial infection for decades are losing their efficacy. In part due to their co-evolution, bacterial pathogens have developed mechanisms to resist almost every antibiotic on the market and we are in desperate need for new, innovative approaches. Writing in Nature Nanotechnology, Zhu et al. present a nanoparticle-based possibility, in which they target bacterial defence mechanisms while simultaneously enhancing the ability of the host immune cells to fight infection.
research
Vision Research Core Receives $3.1 Million Grant
The Vision Research Core has received a $3.1 million grant from the National Eye Institute to provide expertise, facilities, and equipment to foster and expand vision research across the University of Wisconsin-Madison campus.
Big Data, Big Results: UW Selected as Member of IRIS Registry Analytics Consortium
The department is now a member of the American Academy of Ophthalmology’s Intelligent Research in Sight (IRIS) Registry Analytics Consortium. This will allow the access to big data that has the potential to shape future scientific research.
Dr. Julie Mares retires after 32 years of research and service
Mares, a professor in the Department of Ophthalmology and Visual Sciences, retired from UW-Madison on July 14th after a lengthy career exploring the connections between food, a healthy lifestyle, genetics, and nutrition in preserving eye health.
SANDCAT
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Uveitic Macular Edema (Sandcat)
CapriCORN
Comprehensive Analysis of Pathogens, Resistomes, and Inflammatory-markers in the Cornea
RECORDATI MT8
Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops (MT8) for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients
IMVT TED
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
Lab-Grown Retinal Eye Cells Open Door For Clinical Trials to Treat Blindness
Retinal cells grown from stem cells can reach out and connect with neighbors, according to a new study, completing a “handshake” that may show the cells are ready for trials in humans with degenerative eye disorders.